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Summary
 
In this study, we addressed the role of tumor necrosis factor (TNF)-
 
a
 
 and lymphotoxin (LT)-
 
a
 
in the development of colitis and defined the cellular sources (T cells versus non-T cells) of
TNF (TNF-
 
a
 
 and LT-
 
a
 
) relevant to disease development. After adoptive transfer of TNF
 
1
 
/
 
1
 
CD4
 
1
 
CD45RB
 
hi
 
 splenocytes into TNF
 
1
 
/
 
1
 
 recombination activating gene (RAG)2
 
2
 
/
 
2
 
 mice, the
recipients develop massive inflammation of the large intestinal mucosa concurrent with massive
weight loss. In contrast, clinical signs of disease are completely absent in TNF
 
2
 
/
 
2
 
RAG2
 
2
 
/
 
2
 
 recipi-
ents of TNF
 
2
 
/
 
2 
 
CD4
 
1
 
CD45RB
 
hi
 
 T cells, although elevated numbers of interferon-
 
g
 
–producing
cells are present in the colonic mucosa. Surprisingly, upon transfer of TNF
 
2
 
/
 
2
 
CD4
 
1
 
CD45RB
 
hi
 
 T
cells into TNF
 
1
 
/
 
1
 
RAG2
 
2
 
/
 
2
 
 recipients, colitis develops with kinetics similar to those upon transfer
of TNF
 
1
 
/
 
1
 
CD4
 
1
 
CD45RB
 
hi
 
 donor cells. In contrast, no clinical signs of colitis are observed in
TNF
 
2
 
/
 
2
 
RAG2
 
2
 
/
 
2
 
 recipients of TNF
 
1
 
/
 
1
 
CD4
 
1
 
CD45RB
 
hi
 
 T cells. This protection from colitis is
not a consequence of the absence of LT-
 
a
 
, as TNF-
 
a
 
2
 
/
 
2
 
RAG2
 
2
 
/
 
2
 
 recipients of TNF-
 
a
 
2
 
/
 
2
 
CD4
 
1
 
CD45RB
 
hi
 
 T cells are also protected from colitis induction. These results demonstrate the
importance of TNF production by non-T cells of the colonic mucosa in the pathogenesis of colitis
and provide direct evidence for a nonredundant role of TNF-
 
a
 
 in this mouse model of colitis.
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O
 
ver the last few years, several experimental mouse mod-
els for inflammatory bowel disease (IBD),
 
1
 
 which in-
cludes ulcerative colitis and Crohn’s disease in human pa-
tients, have been developed (1). Most of these mouse strains
that spontaneously develop an ulcerative colitis– or Crohn’s
disease–like disorder were generated by targeted disruption
of genes crucially involved in the maintenance of well bal-
anced immune responses, such as the genes encoding TCR
chains (2), MHC class II (2), IL-2 (3), IL-10 (4), or TGF-
 
b
 
(5). In these gene-deficient mice, clinical onset of disease is
accelerated when mice are kept under conventional rather
than specific pathogen–free conditions of maintenance (6,
7). This clearly illustrates the requirement of a balanced im-
mune response against antigens derived primarily from the
gut lumen to maintain local tissue homeostasis in the intes-
tinal mucosa. This assumption is further supported by two
other mouse models of colitis, where transfer of bone mar-
row from wild-type mice into immunocompromised (tg
 
e
 
26)
CD3
 
z
 
-transgenic mice (8) and of CD4
 
1
 
CD45RB
 
hi
 
 T cells
into SCID mice (9, 10) leads to histopathological and clini-
cal signs of colitis. The preferential differentiation of trans-
ferred cells into functional Th1 CD4 T cells in the absence
of functionally heterogeneous lymphoid cell subsets of the
recipient are believed to represent a main pathogenetic fac-
tor in the initiation and progression of the disease in these
mouse models of colitis (11–13).
In the absence of a tightly regulated local immune sys-
tem, the constant exposure of immune effector cells to an-
tigens derived from the gut lumen may lead to an exacer-
bating immune response in the colonic mucosa characterized
by the extensive production of proinflammatory cytokines,
such as TNF-
 
a
 
, IFN-
 
g
 
, and chemokines. An overproduc-
tion of TNF-
 
a
 
 in the affected intestinal mucosa has been well
documented in different animal models of colitis (14–16)
and in human patients with active Crohn’s disease (17–19).
In addition, administration of neutralizing anti–TNF-
 
a
 
 and
lymphotoxin (LT)-
 
a
 
 antibodies in human patients with ac-
tive Crohn’s disease leads to a transient improvement of the
disease (19, 20) and attenuates the development of colitis in
some experimental mouse models (15, 16). Markedly in-
 
1
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 IBD, inflammatory bowel disease; LPL,
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creased production of TNF-
 
a
 
 by macrophages isolated from
lamina propria of affected colons has been reported in pa-
tients with active IBD (18, 21) and also in several animal
models of colitis (22, 23). In addition, infection of mono-
layers of colonic epithelial cell lines with invasive bacteria
leads to the upregulation of proinflammatory cytokines, in-
cluding TNF-
 
a
 
 (24).
TNF-
 
a
 
 is synthesized as a type II membrane-anchored
protein and released in secreted form by a TNF-
 
a
 
 convert-
ing enzyme (25). Secreted TNF-
 
a
 
 is biologically active as a
trimer and binds to two plasma membrane receptors, TNFR
p55 and TNFR p75. The two receptors also bind secreted
trimers of the structurally related LT-
 
a
 
 (formerly also termed
TNF-
 
b
 
). Both receptors have the ability to engage a vari-
ety of overlapping signaling pathways, which may lead to
cell activation or proliferation or apoptosis depending on
the nature and the differentiation state of the target cell.
LT-
 
a
 
 can also bind to a recently defined receptor, Herpes
simplex virus entry mediator (26), and forms heterotrimers
with the membrane-anchored LT-
 
b
 
. LT heterotrimers can
also bind to an additional receptor, LT-
 
b
 
R. TNF-
 
a
 
 and
LT-
 
a
 
 exert overlapping but distinct functions, as exempli-
fied by the distinct effects of TNF-
 
a
 
, LT-
 
a
 
, and LT-
 
b
 
 defi-
ciencies on the presence of secondary lymphoid organs and
their architecture (27, 28).
The aims of this study were to determine (a) if TNF-
 
a
 
/
LT-
 
a
 
 (hereafter referred to as TNF) plays an essential, non-
redundant role in the pathogenesis of colitis in the CD4
 
1
 
CD45RB
 
hi
 
 T cell transfer model of colitis induction, (b) if
TNF production by CD4 T cells is required for disease in-
duction, and (c) if, in the absence of donor T cell–derived
TNF, secretion of TNF by recipient-derived non-T cells is
sufficient for induction of severe colitis. To this end, syn-
geneic CD4
 
1
 
CD45RB
 
hi
 
 T cells from wild-type and TNF-
deficient mice, respectively, were adoptively transferred into
immune-deficient recombination activating gene (RAG)2
 
2
 
/
 
2
 
or TNF-deficient RAG2
 
2
 
/
 
2
 
 mice. The results obtained clearly
demonstrate that TNF is required for induction of severe
colitis in this adoptive cell transfer model. Furthermore, TNF
production by disease-inducing CD4 T cell subsets is not re-
quired for onset of clinically overt colitis, whereas TNF pro-
duced by non-T cells of the recipients is essential for the in-
duction of colitis.
 
Materials and Methods
 
Animals.
 
C57BL/6J 
 
3
 
 129/SvEv-Gpi1c RAG2
 
2
 
/
 
2
 
 mice (de-
rived from the ES cell line EK.CCE 129/SvEv-Gpi1c; reference
29) were provided by Drs. H. Bluethmann and E. Wagner (Basel
Institute for Immunology). TNF
 
2
 
/
 
2
 
 C57BL/6J 
 
3
 
 129/SvEv mice
were generated using the ES cell line GS1 as previously described
(28). C57BL/6J 
 
3
 
 129SvJ mice were obtained from Dr. H.
Bluethmann and the Biotechnology and Animal Breeding Division
of RCC (Füllinsdorf, Switzerland). TNF
 
2
 
/
 
2
 
 mice were back-
crossed with (C57BL/6J 
 
3
 
 129/SvEv-Gpi1c) RAG2
 
2
 
/
 
2
 
 mice in
our animal facility. PCR procedures were used to determine RAG2
and TNF genotypes. Three different primers were used to char-
acterize the RAG2 genotype: Rag1, 5
 
9
 
-GGGAGGACACTCA-
CTTGCCAGTA-3
 
9
 
; Rag2, 5
 
9
 
-AGTCAGGAGTCTCCATCT-
 
CACTGA-3
 
9
 
; and Ragneo, 5
 
9
 
-CGGCCGGAGAACCTGCGTG-
CAA-3
 
9
 
, to yield a 350-bp fragment for the mutated and a 263-bp
fragment for the wild-type allele. The TNF genotype was defined
using the TNF10 (5
 
9-CCTCAGCAAACCACCAAGTGGA-39)
and TNF12 (59-TTGGGCAGATTGACCTCAGCG-39) primers,
where a 350-bp fragment corresponds to wild-type allele, and no
band is detected for the mutant allele. As the RAG22/2, TNF2/2,
and 129 3 B6 mice were obtained from different sources and the
number of backcrosses to C57BL/6J mice was not documented for
the two gene-deficient mouse lines, several control experiments
were performed before using these mouse lines in the CD4 T cell
transfer model of colitis to exclude potential graft-versus-host reac-
tions. These controls included mixed lymphocyte reactions using
splenocytes from donor and recipients as responders and, upon ir-
radiation (2,000 rads), as stimulators, as well as the careful histo-
pathological examination of small intestine, skin, and liver from all
experimental animals. Both the mixed lymphocyte reactions and
the histopathological analyses revealed no indications of minor his-
toincompatibilities or graft-versus-host reactions in all of the differ-
ent donor–recipient combinations used (data not shown).
TNF-a2/2 mice (C57BL/6) were obtained from Dr. M.
Marino (Ludwig Institute for Cancer Research, New York, NY)
for subsequent backcrossing to C57BL/6J RAG22/2 mice (.10
backcross generations; obtained from E. Wagner, Basel Institute
for Immunology). The TNF-a genotype was defined using three
different primers (TNF-a1, 59-AGATAGCAAATCGGCTGA-
CGG-39; TNF-a2, 59-ATCAGTTCTATGGCCCAGACC-39;
and TNF-aneo, 59-CCTTCTATCGCCTTCTTGACG-39),
where TNF-a1/TNF-aneo yielded a band of 1,200 bp for the
mutant allele, and the TNF-a1/TNF-a2 primers yielded a band of
750 bp for the wild-type allele. Mice were kept at specific patho-
gen–free conditions in the central animal facility of the Medical
School, University of Bern, Bern, Switzerland.
mAbs Used for Cell Sorting and Enzyme-linked Immunospot Assay.
PE-conjugated anti-CD4 (clone GK1.5), FITC-conjugated anti-
CD45RB (clone 16A), biotin-conjugated anti–TNF-a pAb, bio-
tin-conjugated anti–IL-4 mAb (clone BVD6-24G2), anti–TNF-a
mAb (clone MP6-XT22), and anti–IL-4 mAb (BVD4-1D11)
were purchased from PharMingen. Protein G–purified antibodies
from the hybridoma supernatants anti-B220 (clone RA3-6B2),
anti–macrophage-specific mAb (clone F4/80), anti-CD8a (clone
53-6.7), anti–IFN-g mAb (clone AN181724), anti–Mac-1 mAb
(clone M1/70), and anti–IFN-g mAb (clone OIE703B2) were
biotinylated or FITC conjugated according to standard protocols.
Isolation of Intestinal Lamina Propria Lymphocytes. Lamina pro-
pria lymphocytes (LPLs) from small and large bowel were isolated
as previously described (30). In brief, small pieces of appropriate
intestinal tissues were incubated for 20 min at 378C in Ca21- and
Mg21-free HBSS containing 2% horse serum (GIBCO-BRL Life
Technologies), 1 mM dithiothreitol, and 0.5 mM EDTA. After
washing pieces of intestine with HBSS containing 5% horse se-
rum, the tissues were incubated with 100 U/ml collagenase
(Sigma Chemical Co.) and 10 mg/ml DNase (Boehringer Mann-
heim) twice for 60 min each at 37°C. Cells were passed through
70- and then 40-mm nylon cell strainers and further fractionated
on a 40–70% Percoll gradient (Pharmacia Biotech; 15 min, 800 g,
room temperature). For the sorting of macrophages and CD4
cells, isolated cells from small and large bowel were stained with
PE-conjugated anti-CD4 mAb, FITC-conjugated anti-F4/80,
and FITC-conjugated anti-Mac-1 mAb for subsequent sorting on
a FACS Vantage™ (Becton Dickinson).
Isolation and Purification of CD41CD45RBhi versus CD41CD45RBlo
Splenocytes. After osmotic lysis of erythrocytes, splenocytes were1481 Corazza et al.
incubated with 0.5–1 mg biotinylated anti-CD8a and anti-B220
mAb per 106
 cells for 15 min on ice. Avidin magnetic beads
(Miltenyi Biotec) were used as second step reagents, and the
CD8a1 and B2201 splenocytes attached to the beads were re-
moved by magnetic separation. The negative fraction, enriched
for CD4 T cells, was stained using FITC-conjugated anti-CD45RB
mAb and PE-conjugated anti-CD4 mAb. Subsequently, CD4 T
cells were sorted according to the expression of CD45RB on a
FACS Vantage™. CD4 T cells were divided into three different
subpopulations (low, intermediate, and high) according to ex-
pression level of CD45RB. The CD4 cell subset with lowest ex-
pression of CD45RB was collected as CD45RBlo, and the subset
with highest expression of CD45RB was termed CD45RBhi.
CD41 T cells with intermediate cell surface expression of CD45RB
were discarded.
Reconstitution of RAG22/2 Mice with CD4 T Cell Subpopulations.
Sorted CD41CD45RBhi and CD41CD45RBlo T cells were washed
and resuspended at 106
 cells/ml in sterile PBS. 2 3 105 cells were
injected intraperitoneally into each of 8–12-wk-old recipient
mice. Upon transfer, body weight of recipient mice was measured
every other day. Mice were killed and analyzed either on day 10
or between 3 and 4 wk after adoptive transfer when the mice
showed a weight loss between 20 and 30% of their initial weight
or 6 wk after transfer in experimental groups where no sign of
colitis was observed.
Histology. Intestinal tissue sections from large and small bowel
were fixed in 4% paraformaldehyde (in 13 PBS) for subsequent
paraffin embedding or frozen in O.C.T. compound (Bayer AG)
for preparation of cryostat sections. Paraffin-embedded sections
were cut and stained with hematoxylin and eosin. To assess the
histopathological alterations in the colon present after adoptive
transfer of CD4 T cell subpopulations from different donors, a
scoring system was established using the following parameters: (a)
cellular infiltration in the lamina propria of the large bowel (score
from 0 to 3); (b) mucin depletion (score from 0 to 2); (c) crypt
abscesses (score from 0 to 2); (d) epithelial erosion (score from 0 to
2); (e) hyperemia (score from 0 to 3); and (f) thickness of colonic
mucosa (score from 1 to 3). Hence, the range of histopathological
scores was from 1 (no alteration) to 15 (most severe signs of colitis).
Preparation of 35S-labeled RNA Probes. A 1,108-bp cDNA frag-
ment of the murine TNF-a gene (position 1–1,108; provided by
Genentech Inc.) and a 900-bp EcoRI–HindIII cDNA fragment of
the IFN-g gene (provided by Dr. K. Arai, DNAX, Inc., Palo Alto,
CA) were subcloned into pGEM-2 (Promega Corp.). After lineariza-
tion of both plasmids, sense and antisense RNA probes were prepared
using the appropriate RNA polymerase as previously described (31).
In Situ Hybridization. Serial frozen sections of intestinal tissue
were hybridized in situ with an antisense RNA probe specific for
the TNF-a and IFN-g genes. In situ hybridizations were per-
formed as previously described (31). In brief, cryostat sections were
fixed in 4% paraformaldehyde in PBS for 20 min, washed in PBS,
and incubated in the presence of 1 mg/ml proteinase K (Boeh-
ringer Mannheim) at 37°C for 30 min. After postfixation and
acetylation, the hybridization was performed with 2 3 105 cpm of
35S-labeled RNA probe per microliter of hybridization solution
for 18 h at 48°C. After digestion of nonhybridized single-stranded
RNA and washing, the slides were dipped in NTB2 nuclear track
emulsion (Eastman Kodak Co.). The slides were exposed for 3 wk
in the dark at 4°C, developed, and counterstained with nuclear
fast red (Sigma Chemical Co.) by standard techniques.
Enzyme-linked Immunospot Assay. To determine the number of
TNF-a–, IL-4–, and IFN-g–producing cells in the LPLs of large
versus small intestine, an enzyme-linked immunospot (ELISPOT)
assay was performed as previously described (32). In brief, nitro-
cellulose-backed microtiter plates (96-well; Millipore Corp.) were
coated at 4°C overnight with anti–TNF-a, anti–IFN-g, and anti–
IL-4 mAbs and subsequently blocked with TBS containing 5%
BSA. After washing the plate with TBS containing 0.025% Tween-
20, freshly isolated LPLs or sorted CD4 T cells and macrophages
were incubated in IMDM containing 10% FCS in a CO2 incubator
at 37°C overnight. The plates were extensively rinsed with TBS
plus 0.025% Tween-20 and incubated for 2 h at 37°C with biotiny-
lated anti–TNF-a pAb, anti–IFN-g mAb, and anti–IL-4 mAb, re-
spectively. The plate was subsequently rinsed and incubated for 2 h
at 37°C with avidin–alkaline phosphatase (Sigma Chemical Co.),
diluted 1:1000. 5-bromo-4-chloro-3-indolyl phosphate/nitroblue
tetrazolium (BCIP/NTB) solution (Kirkegaard and Perry Labs.,
Inc.) was used as a substrate for the alkaline phosphatase. Positive
spots were counted under a dissecting microscope.
Results
When 2 3 105 CD41CD45RBhi T cells from B6 3 129
donor animals (TNF1/1) were transferred into sex-matched,
8–10-wk-old syngeneic RAG22/2 mice, the recipients
rapidly started to lose weight 12–14 d after adoptive T cell
transfer. This dramatic wasting disease led to an average
weight loss of 25–30% 24 d after transfer and is associated
with clinical signs of severe colitis, in particular, persistent
diarrhea and occasionally also bloody stool and anal pro-
lapses. RAG22/2 recipients of 2 3 105 CD41CD45RBlo T
cells did not, however, show weight loss, and clinical signs
of colitis were completely absent throughout the entire ob-
servation period (Fig. 1 A).
To assess the contribution of TNF-a and the structurally
related LT-a (TNF-b) to the course of disease in this
mouse model of colitis, B6 3 129 RAG22/2 mice were
first backcrossed to TNF-deficient B6 3 129 mice (TNF2/2)
to obtain TNF2/2RAG22/2 mice. The consequences of an
adoptive transfer of CD41CD45RBhi
 T cells from TNF2/2
donors into TNF2/2RAG22/2 mice on the body weights
of the recipients is depicted in Fig. 1 B. Throughout the
entire observation period of 42 d, no sign of weight loss
was observed. Clinical signs of colitis, such as persistent di-
arrhea, or more severe signs, such as anal prolapse or bloody
stool, were absent in all animals throughout the entire ob-
servation period. No difference in the kinetics of body
weight or clinical signs of colitis were apparent when TNF2/2
RAG22/2 recipients of TNF2/2CD41CD45RBhi and CD41
CD45RBlo T cells were compared (Fig. 1 B).
When recipients of CD41CD45RBhi T cells had lost
between 20 and 30% of their initial body weight or at the
end of the observation period on day 42 after transfer, all
mice were killed and part of each colon was paraffin em-
bedded for subsequent detailed histopathological analyses.
To quantitate the histological alterations present in the
large intestines of recipient mice, a semiquantitative colitis
score system ranging from 1 (no histopathological alterations)
to 15 (most severe histopathological alterations) was estab-
lished (see Materials and Methods). The results of these mi-
croscopical analyses of colonic tissue sections are summa-
rized in Fig. 2 A. TNF1/1RAG22/2 recipients of TNF1/11482 The Role of Tumor Necrosis Factor in the Pathogenesis of Colitis
CD41CD45RBhi T cells revealed massive alterations of the
colon, with colitis scores between 12 and 15 (mean 13.2) for
individual animals. Control TNF1/1 RAG22/2 mice recon-
stituted with TNF1/1CD41 CD45RBlo splenocytes, how-
ever, showed only minimal signs of histopathological alter-
ations (mean 4.5). Histological changes of the colon in
TNF2/2RAG22/2 mice after adoptive transfer of TNF2/2
CD41CD45RBhi T cells were minimal to moderate (mean
5.8) and comparable to the colitis scores observed in TNF2/2
RAG22/2 recipients of the corresponding TNF2/2CD41
CD45RBlo T cells (mean 4.5; Fig. 2 A). Representative ex-
amples of cross-sections of the colon from a TNF1/1
RAG22/2 recipient of colitis-inducing TNF1/1CD41
CD45RBhi T cells (colitis score 14) and from a TNF2/2
RAG22/2 recipient of TNF2/2CD41CD45RBhi T cells
(colitis score 5) are shown in Fig. 2, B and C, respectively.
Extensive inflammatory cell infiltrates, glandular elongation,
loss of goblet cells, epithelial erosion, and crypt abscesses
were observed in colonic tissue sections of mice affected with
wasting disease (Fig. 2 D). In contrast, minimal colonic pa-
thology was observed in tissue sections from TNF2/2
CD41CD45RBhi T cells®TNF2/2RAG22/2 mice. Lim-
ited cellular infiltration, together with minimal glandular
elongation and minimal loss of goblet cells, was present in
the lamina propria and submucosa, whereas epithelial ero-
sion and crypt abscesses were completely absent in these
mice (Fig. 2 E).
These experiments clearly demonstrate that TNF is re-
quired for the induction of clinical and histopathological
signs of severe colitis and epithelial erosion of the intestinal
wall. Thus, we attempted to determine if TNF production
by the transferred colitogenic CD41CD45RBhi T cells is
required for the development of colitis or whether local
production of TNF by resident non-T cells of the recipi-
ents is sufficient for disease induction and perpetuation. To
this end, two reciprocal donor–recipient combinations
were analyzed: transfer of TNF1/1 CD4 T cell subsets into
TNF2/2RAG22/2 recipients and transfer of TNF2/2 CD4
T cell subsets into TNF1/1RAG22/2 recipients. The con-
sequences of adoptive transfer of TNF2/2CD41CD45RBhi
Figure 1. TNF-a/LT-a is essential to in-
duce wasting disease. Reconstitution of
RAG22/2 mice with 2 3 105 TNF1/1
CD41CD45RBhi T cells induces colitis
characterized by weight loss (A), whereas no
weight loss is detected in TNF2/2 recipients
reconstituted with 2 3 105 TNF2/2
CD41CD45RBhi T cells (B). As negative
controls, mice were injected with 2 3 105
CD41CD45RBlo T cells. The change in
weight is expressed as percentage of the
weight at the time of cell transfer. Data rep-
resent the mean values 6 SD of four to five
mice per group. Experiments were repeated
at least three times.
Figure 2. Colitis scores and histopathology of the colons from TNF1/1
RAG22/2 recipients of TNF1/1CD41CD45RBhi T cells (d) and CD41
CD45RBlo T cells (s) and from TNF2/2RAG22/2 recipients of TNF2/2
CD41CD45RBhi/lo T cells. (A) The colitis scores shown for individual
mice represent the total of individual scores for cellularity, mucin deple-
tion, crypt abscess, epithelial erosion, hyperemia, and thickness of the
colon as described in Materials and Methods. (B and D) Tissue sections
of the colon from TNF1/1RAG22/2
  recipients of TNF1/1CD41
CD45RBhi T cells (colitis score 12) and (C and E) from TNF2/2
RAG22/2
 recipients of TNF2/2CD41CD45RBhi T cells (colitis score 5).
Hematoxylin and eosin staining; magnifications: B and C, 93 and D and
E, 603.1483 Corazza et al.
T cells into TNF1/1RAG22/2 mice on body weights are
illustrated in Fig. 3 A. Similar to when TNF1/1CD41
CD45RBhi T cells were transferred into TNF1/1RAG22/2
mice, recipients started to lose weight 12–14 d after adop-
tive T cell transfer. This weight loss paralleled with clinical
signs of colitis such as persistent diarrhea, anal prolapse, and
bloody stool. TNF2/2RAG22/2 recipients of TNF1/1 CD41
CD45RBhi T cells, however, did not show any clinical signs
of colitis during the entire observation period (Fig. 3 B).
The results of the semiquantitative histopathological
analysis of the colon in these two different donor–recipient
combinations are shown in Fig. 4 A. Massive alterations of
the colon with colitis scores ranging from 10 to 14 for indi-
vidual mice (mean colitis score 11.7) were observed in tissue
sections from TNF1/1RAG22/2 recipients of TNF2/2 CD41
CD45RBhi T cells. A representative cross-section of an af-
fected colon from this donor–recipient combination is shown
in Fig. 4 B (colitis score 12). Hence, CD41CD45RBhi T cells
from TNF2/2 donors induce histological alterations of the
colonic mucosa comparable to those of CD41CD45RBhi
T cells from TNF1/1 donors upon transfer into TNF1/1
RAG22/2 mice (Fig. 4 D). In contrast, only minimal co-
lonic pathologies were observed in TNF2/2RAG22/2 mice
reconstituted with TNF1/1CD41CD45RBhi
  splenocytes
(Fig. 4, A, C, and E), demonstrating that TNF produced
exclusively by transferred CD4 T cells is not sufficient to
induce wasting disease. The absence of a wasting disease is
associated with only minimal to moderate histopathological
signs of colitis, with scores ranging from 2 to 8 for individual
animals of this group (mean colitis score 4.7). Control animals
of both groups reconstituted with the corresponding CD41
CD45RBlo T cells showed only mild to moderate histo-
pathological alterations of the colonic mucosa (Fig. 4 A).
Whereas protection from onset of severe colitis in TNF2/2
RAG22/2 mice reconstituted with TNF2/2CD41 CD45RBhi
T cells can be attributed to the complete absence of TNF
production in both transferred T cells and recipient cells,
the absence of clinical signs of colitis and severe histopatho-
Figure 3. TNF-a/LT-a produced by recipi-
ent non-T cells is required and sufficient to in-
duce clinical signs of colitis. Reconstitution of
TNF1/1 RAG22/2 mice with 2 3 105 TNF2/2
CD41CD45RBhi T cells induces colitis charac-
terized by weight loss (A), whereas no weight
loss is observed in TNF2/2 recipients reconsti-
tuted with 2 3 105 TNF1/1CD41 CD45RBhi
T cells (B). As negative controls, mice were in-
jected with 2 3 105 CD41CD45RBlo T cells.
Data represent the mean values 6 SD of four to
five mice per group. Experiments were re-
peated at least three times.
Figure 4. Colitis scores and histopathology of colons from TNF1/1
RAG22/2 recipients of TNF2/2CD41CD45RBhi T cells (d) and CD41
CD45RBlo T cells (s) and from TNF2/2RAG22/2 recipients of TNF1/1
CD41CD45RBhi/lo T cells (A). (B and D) Tissue sections of the colon
from a TNF2/2CD41CD45RBhi®TNF1/1RAG22/2 mouse (colitis
score 12) and (C and E) from a TNF1/1CD41 CD45RBhi®TNF2/2
AG22/2 mouse (colitis score 4). Hematoxylin and eosin staining; magnifi-
cations: B and C, 93 and D and E, 1203.1484 The Role of Tumor Necrosis Factor in the Pathogenesis of Colitis
logical alterations in the colons of TNF2/2 RAG22/2 mice
reconstituted with potentially TNF-producing TNF1/1
CD41CD45RBhi T cells is less obvious. Thus, we defined
the frequency of TNF-a–producing cells in the colon in
the four different donor–recipient combinations to assess
whether protection from colitis in the TNF1/1CD41
CD45RBhi T cells into the TNF2/2 RAG22/2 group is as-
sociated with low production of TNF-a by donor-derived
T cells. To this end, inflammatory cells were isolated from
the colonic mucosa for subsequent analysis in an ELISPOT
assay. The results obtained clearly show that TNF-a is pro-
duced by a massive number of inflammatory cells isolated
from the colons of TNF1/1 RAG22/2 mice, transferred with
either TNF1/1 or TNF2/2 CD41CD45RBhi T cells 24 d
after adoptive transfer of the respective CD41CD45RBhi T
cell subset. In contrast, in the experimental group that did
not develop colitis, i.e., in TNF2/2RAG22/2 mice recon-
stituted with TNF1/1CD41 CD45RBhi T cells, TNF-a
was produced only by very few infiltrating cells isolated
from the large intestinal mucosa. This demonstrates that
only a small fraction of transferred CD4 T cells produces
TNF-a in the colonic mucosa of TNF2/2RAG22/2
 recip-
ients (Fig. 5). To further confirm that absence of colitis in-
duction and perpetuation of disease correlate with the ab-
sence of significant numbers of TNF-a–producing cells in
the colonic mucosa, we also determined the frequency of
TNF-a–producing cells in the colonic mucosa of recipients
of CD41CD45RBlo T cells, i.e., in the control groups that
did not show signs of clinical or histopathological colitis. As
seen in Fig. 5, right panels, absence of colitis induction al-
ways correlates with the absence of TNF-a production by
isolated colonic cells from recipients of CD41CD45RBlo
splenocytes.
To determine if the absence of TNF production by host-
derived cells affects the induction of TNF production in
the transferred CD4 T cells, thus resulting in the low fre-
quency of TNF-a–producing T cells detected in TNF2/2
RAG22/2 recipients of TNF1/1 colitogenic T cells (Fig. 5),
we assessed the frequency of TNF-a–producing cells in
fractionated CD4 T cells and, as a main TNF-a–produc-
ing, recipient-derived cell type, in macrophages isolated
from the affected colonic mucosa of TNF1/1RAG22/2 re-
cipients of TNF1/1CD41CD45RBhi T cells. 8.7‰ of the
macrophages isolated from the affected colons produced
TNF-a, whereas only 0.17‰ of isolated colonic CD4 T
cells produced TNF-a in an ELISPOT assay. The frequency
of TNF-a–secreting macrophages in the colonic mucosa in
diseased animals was z10-fold higher than in macrophages
isolated from the small intestinal mucosa of the same ani-
mals, where no signs of histopathological alterations were
observed (8.7 and 0.8‰ TNF-a–producing macrophages,
respectively).
To assess how the presence or absence of TNF produc-
tion by recipient cells and donor-derived CD4 T cells
might affect the cytokine pattern produced in the colonic
mucosa, ELISPOT assays were performed to determine the
frequency of IL-4– and IFN-g–secreting cells in the isolated
inflammatory cells from the colonic mucosa. In all four
combinations of transfer, CD41CD45RBhi T cells prefer-
entially induced production of the Th1 cytokine IFN-g in
the colonic mucosa. Similar frequencies of IFN-g–produc-
ing infiltrating CD4 T cells were detected in experimental
groups of mice that developed severe colitis and in recipi-
ent mice that were protected from onset of severe disease
(Fig. 5). Hence, production of IFN-g does not correlate with
the presence of clinical signs of colitis but correlates with
the transfer of CD41CD45RBhi T cells, as the frequency of
IFN-g–producing cells is markedly reduced in recipients of
CD41CD45RBlo T cells from both TNF1/1 and TNF2/2
donor mice. Colonic IL-4–producing cells, however, were
less frequent in recipients of CD41CD45RBhi T cells when
compared with recipients of CD41CD45RBlo T cells. The
differences in IL-4 production by infiltrating CD4 T cells
Figure 5. Cytokine production by inflammatory cell infiltrates in the
colonic mucosa of the four different donor–recipient combinations after
transfer of CD41CD45RBhi and CD41CD45RBlo T cells. The frequency
of TNF-a–, IFN-g–, and IL-4–producing cells (in ‰) as determined by
ELISPOT, with isolated cells of the colonic mucosa indicated as a mean
values 6 SD; n 5 number of mice analyzed per group.1485 Corazza et al.
were only minimal among the four recipient groups of CD41
CD45RBhi T cells (Fig. 5).
To assess not only the frequency but also the histological
distribution of TNF-a–producing cells, in situ hybridiza-
tion of cryostat sections of the affected colonic mucosa (day
24 after cell transfer) with TNF-a gene probes were per-
formed. As shown in Fig. 6, A and E, high frequencies of
TNF-a mRNA–expressing cells were detected on colonic
tissue sections of TNF1/1RAG22/2 recipients of TNF1/1
CD41CD45RBhi T cells (Fig. 6 A; colitis score 12) and
TNF1/1RAG22/2
 recipients of TNF2/2CD41CD45RBhi
T cells (Fig. 6 E; colitis score 14). In both groups, TNF-a
mRNA–expressing cells were not randomly distributed
over the entire colonic mucosa but were preferentially
clustered in the apical areas of colonic crypts proximal to
the gut lumen and also at sites close to epithelial erosions of
the colonic mucosa. In contrast, only a limited number of
TNF-a mRNA CD4 T cells were detected in TNF2/2
RAG22/2 recipients of TNF1/1CD41CD45RBhi T cells
(Fig. 6 G). In these mice, rare TNF-a mRNA–expressing
Figure 6. In situ hybridization of cryostat sec-
tions from colonic specimens of the four different
donor–recipient combinations 24 d after adoptive
cell transfer. (A and B) TNF1/1CD41CD45RBhi®
TNF1/1 RAG22/2 mice; (C and D) TNF2/2CD41
CD45RBhi®TNF2/2RAG22/2 mice; (E and F)
TNF2/2CD41CD45RBhi®TNF1/1RAG22/2 mice;
and (G and H) TNF1/1CD41CD45RBhi® TNF2/2
RAG22/2 mice, using 35S-labeled antisense mRNA
probes of TNF-a (A, C, E, and G) and IFN-g (B,
D, F, and H). TNF-a mRNA–expressing cells are
preferentially located proximal to the lumen of the
colon in affected mice (A and C). In situ hybridiza-
tion with sense probes of the TNF-a (I) and IFN-g
genes (J) were used as negative controls. Magnifica-
tion 120.1486 The Role of Tumor Necrosis Factor in the Pathogenesis of Colitis
CD4 T cells were almost randomly distributed in the co-
lonic lamina propria. In situ hybridization with an IFN-g–
specific probe revealed strong IFN-g mRNA expression in
the colonic mucosa of all groups of recipients of CD41
CD45RBhi T cells (Fig. 6, B, D, F, and H). In the two donor–
recipient combinations in which no severe colitis was in-
duced, TNF2/2RAG22/2 recipients of TNF1/1 (Fig. 6 H)
and TNF2/2CD41CD45RBhi T cells (Fig. 6 D), the strong
IFN-g mRNA expression observed in some mice was al-
ways associated with elevated cellular infiltration of the co-
lonic mucosa (colitis score $7). IFN-g mRNA1 cells were
not, however, restricted to the sites proximal to the lumen
of the colon but were focally distributed throughout the
entire colonic mucosa (Fig. 6). As a negative control, af-
fected intestinal colonic tissues were hybridized with sense
probes of the TNF-a (Fig. 6 I) and IFN-g genes (Fig. 6 J).
To further determine if the correlation between absence of
clinical signs of colitis and absence of TNF-a–expressing
cells is also true at early time points of disease induction
where histopathological signs of a deleterious inflammation
of the colon are still absent, in situ hybridization for the lo-
calization of TNF-a mRNA–expressing cells were per-
formed on colonic tissue obtained on day 10 (Fig. 7). De-
spite the absence of significant histopathological alterations
of the colonic mucosa 10 d after transfer in the two groups
that later developed colitis (TNF1/1CD41CD45RBhi®
TNF1/1RAG22/2 (Fig. 7, A and B) and TNF2/2CD41
CD45RBhi®TNF1/1RAG22/2
 mice (Fig. 7, C and D), the
frequency of TNF-a mRNA–expressing cells was compa-
rable to that observed on day 24 after cell transfer with a
preferential localization of TNF-a mRNA in cells close to,
or even facing, the intestinal lumen. In TNF2/2RAG22/2
recipients of TNF1/1CD41 CD45RBhi T cells that did not
develop clinical colitis, TNF-a mRNA–expressing cells
were almost completely absent on day 10 (Fig. 7 F).
To exclude the possibility that the failure of TNF1/1
CD41CD45RBhi T cells to induce colitis in TNF2/2
RAG22/2 mice was due to the absence of peripheral lymph
nodes and Peyer’s patches or the aberrant splenic architec-
ture found in mice deficient for LT-a (28), we decided to
back-cross C57BL/6J TNF-a2/2 mice to the syngeneic
RAG22/2 background for subsequent transfer experiments
using TNF-a2/2 mice as donors. As depicted in Fig. 8 A,
transfer of the CD41CD45RBhi T cells initially leads to a
slight decrease in body weight around day 10 after cell
transfer, but thereafter, recipients begin to gain weight to
reach the body weight of the control animals transferred
with the same number of CD41CD45RBlo T cells from
Figure 7. Histopathological alterations
and TNF-a mRNA expression before
clinical onset of colitis. Day 10 after trans-
fer of TNF1/1CD41CD45RBhi T cells
into TNF1/1RAG22/2 recipients (A and
B); TNF2/2CD41CD45RBhi T cells into
TNF1/1RAG22/2 recipients (C and D);
and TNF1/1CD41CD45RBhi T cells into
TNF2/2RAG22/2 recipients (E and F). A,
C, and E, hematoxylin and eosin staining;
B, D, and F, in situ hybridization; magnifi-
cation 60.1487 Corazza et al.
the same donor animals. During the entire observation pe-
riod of 35 d, the recipients of CD41CD45RBhi T cells did
not show any signs of clinical colitis such as loose stool or
even diarrhea or anal prolapse. The histopathological analy-
ses performed 35 d after adoptive cell transfer demonstrated
only mild signs of colitis, in particular focal accumulation of
inflammatory cells. The histopathological scores determined
for recipients of CD41CD45RBhi and CD41CD45RBlo T
cells were not markedly different and even overlapped (Fig.
8 B). Microphotographs of the colon from a TNF-a2/2
RAG22/2 recipient of TNF-a2/2CD41 CD45RBhi T cells
35 d after adoptive transfer are shown in Fig. 8, C and D.
Discussion
In recent years, several studies attempted to elucidate the
role of TNF-a in IBD. Overproduction of TNF-a has
been well documented in the affected intestinal mucosa in
different animal models (14, 16, 33) and human patients
with active Crohn’s disease (17, 19). After administration
of anti-TNF-a/LT-a (TNF) antibodies, an attenuation of
disease progression has been observed in different mouse
models of colitis and patients with IBD (15, 16, 19). How-
ever, the beneficial effects of an anti-TNF treatment are of-
ten transient (19). The reasons for the limited effects are
not entirely understood and can possibly be attributed to a
variety of factors, including the limited bioavailability of
TNF-neutralizing agents at the site of mucosal lesions and
redundant effects mediated by TNF at various stages of dis-
ease. Furthermore, recent results suggest that neutralizing
antibodies to TNF can reverse suppressive effects mediated
by TNF-a on T cells in vivo (34), thus leading to higher
functional and proliferative activity of disease-promoting T
cells. Such an antiinflammatory effect of TNF-a has been
demonstrated by Liu et al. in experimental allergic enceph-
alomyelitis in mice where TNF-a can limit the extent and
duration of severe central nervous system pathology (35).
Hence, the accelerated onset of weight loss and clinical
signs of colitis in TNF1/1RAG22/2 mice after transfer of
CD41CD45RBhi T cells from TNF2/2 rather than TNF1/1
donors (Fig. 3) is thus in agreement with the notion that
systemic TNF-a may attenuate T cell functions in vivo.
On the other hand, our study also unambiguously demon-
strates the nonredundant role of TNF in the induction of
colitis in this mouse model.
The nature of the TNF-producing cells (T cells versus
non-T cells) relevant for the development of colitis in ex-
perimental animal models and human patients with IBD
has not been directly determined so far. Several studies (22,
36) found large numbers of TNF-a–secreting macrophages
in the inflamed colonic mucosa. Other studies reported
high frequencies of TNF-producing T cells, in particular
CD41 T cells, in the affected colonic mucosa (14, 37), sug-
gesting that TNF produced by T cells may represent a crit-
ical factor directly affecting the extent of disease. Our re-
sults, however, clearly indicate that CD41 T cell–produced
TNF is neither sufficient nor required for induction of dis-
ease in this mouse model of colitis and that TNF produc-
tion by recipient non-T cells is essential and sufficient for
induction of severe histopathological alterations and onset
Figure 8. TNF-a plays a nonre-
dundant role in the development of
colitis. Kinetics of the body weight
of TNF-a2/2 (LT-a1/1) RAG22/2
mice upon transfer of 2 3 105 TNF-
a2/2 (LT-a1/1) CD41CD45RBhi T
cells (j) and 2 3 105 TNF-a2/2
(LT-a1/1) CD41CD45RBlo T cells
(h). Data are the mean 6 SD of
eight CD41CD45RBhi  and four
CD41CD45RBlo  mice (A). Colitis
scores of colons from TNF-a2/2
RAG22/2 recipients of TNF-a2/2
CD41CD45RBhi T cells (d) and
from CD41CD45RBlo T cells (s)
are  compared with colitis scores of
TNF1/1RAG22/2 recipients of
TNF1/1 CD41 CD45RBhi and CD41
CD45RBlo T cells (B). Tissue sections
of the colon from a TNF-a2/2 CD41
CD45RBhi®TNF-a2/2RAG22/2
mouse (colitis score 5) (C and D).
Hematoxylin and eosin staining; mag-
nifications: C, 93 and D, 603.1488 The Role of Tumor Necrosis Factor in the Pathogenesis of Colitis
of clinical signs of colitis. The observed preferential TNF-a
production by colonic macrophages and their nonrandom
distribution close to sites with epithelial erosion (data not
shown) implies an important role of this cell subset in the
pathogenesis of colitis. However, it remains to be deter-
mined if macrophages are the only recipient-derived cellu-
lar source of TNF-a crucial for the development of clinical
signs of disease. In particular, as intestinal epithelial cells
have also been demonstrated to produce TNF-a (24), it is
possible to speculate that epithelial cells are induced di-
rectly or indirectly by activated CD4 T cells to produce
TNF-a. This assumption is supported by the results of in
situ hybridizations of tissue specimens from the affected co-
lon, where TNF-a mRNA–expressing cells are consis-
tently observed in the intestinal epithelium even at early
stages of disease when only minimal infiltration of the co-
lon with inflammatory cells is observed (Fig. 7). Although
the number of cells recovered from the colonic mucosa
from animals at the time of initial signs of weight loss, i.e.,
between days 10 and 14 after cell transfer, was too low for a
quantitative assessment of the frequency of TNF-a–secret-
ing cells, the results of the in situ hybridizations clearly in-
dicate that TNF-a mRNA expression is detectable at levels
similar to those observed on day 24, during the most active
stage of disease. This indicates that elevated TNF-a expres-
sion is not the consequence of the strong inflammatory cell
infiltrates but in fact precedes the severe histopathological
alterations. As comparable numbers of TNF-a mRNA–
expressing cells are detected in TNF1/1RAG22/2 mice re-
constituted with either TNF1/1 or TNF2/2 CD41CD45RBhi
T cells, we conclude that recipient non-T cells are already
the main TNF-producing cell type at the very early stages
of disease. Similar findings have been reported in IL-2–
deficient mice where, in the intestines of 10-d-old mice,
20-fold higher TNF-a mRNA expression levels were ob-
served compared with older mice (24). This increase, how-
ever, was found both in the small and the large intestines,
whereas in our model, elevated expression of TNF-a
mRNA as detected by in situ hybridization was restricted
to the colon (data not shown).
The precise effects mediated by locally produced TNF-a
during development of colitis must remain speculative. The
location of TNF-a–producing cells close to or even in the
colonic epithelium concomitant with the appearance of
histopathological alterations and subsequent clinical onset
of severe colitis suggests that TNF-a may have a direct cyto-
toxic effect on epithelial cells by inducing an accelerated
apoptosis of epithelial cells. Induction of TNF-a–mediated
apoptosis via TNFR p55 in intestinal epithelial cells, first at
the top of the villi and subsequently extending along the
villus axis towards the intestinal crypts, has been recently
reported by Guy-Grand et al. (38) and Piguet et al. (39).
Such an enhanced apoptosis of colonic epithelial cells may
lead to the extensive erosion of the epithelium with subse-
quent severe inflammatory reactions, as observed during
later stages of disease. Furthermore, TNF-a can induce the
production of other inflammatory mediators such as free
radicals, tissue degrading enzymes such as matrix metallo-
proteases (40, 41), and further proinflammatory cytokines,
including IL-1b (42). TNF-a can further amplify a local
immune reaction through its effects on professional APCs
such as dendritic cells, which are activated by TNF-a to
become potent inducers of immune reactions (43).
Because LT-a, in addition to TNF-a, either as a homo-
trimer or heterotrimer, also binds to TNFR p55 and TNFR
p75, we decided to use donor and recipient mice that were
deficient for both TNF-a and LT-a (TNF2/2). The pro-
tection of TNF2/2RAG22/2 recipients of TNF1/1CD41
CD45RBhi T cells from developing severe colitis clearly
demonstrates that not only CD4 T cell–derived TNF-a
but also CD4 T cell–produced LT-a is not sufficient for
disease induction, nor is it required for initiation and pro-
gression of disease. The observed protection of TNF-a2/2
LT-a1/1RAG22/2 mice from onset of colitis upon transfer
of TNF-a2/2CD41CD45RBhi T cells directly demon-
strates that TNF-a plays a nonredundant role in the devel-
opment of colitis, and its functions cannot be compensated
for by the action of LT-a. These findings confirm the re-
sults of a previous report on the respective roles of TNF-a
and LT-a in a mouse model of experimental allergic en-
cephalomyelitis in which no redundancy in the functions
of TNF-a and LT-a was observed in vivo (44). The ob-
served protection of TNF-a2/2 recipients from colitis in-
duction seems to be in contrast to the reported attenuation
of disease when experimental mice are treated with a solu-
ble LT-bR–human Fcg1 fusion protein in two models of
colitis, CD41CD45RBhi T cells®SCID mice and bone
marrow–transplanted tge26 mice (45). However, it cannot
be excluded that binding of the soluble LT-bR–human
Fcg1 fusion protein to activated, LT-bearing transferred T
cells or recipient cells may affect the subsequent functional
differentiation and/or survival of these LT-b1 cells. Evi-
dence for opsonizing effects of receptor–Fcg fusion proteins
bound to cell surface ligands has recently been provided by
the recombinant cell surface expression of human Fcg in a
reversed opsonization (46).
TNF-a has also been previously found to affect the traf-
ficking of T cells into distinct organs such as the central
nervous system (47). However, when we examined the pres-
ence of CD4 T cells in the colonic mucosa at early time
points (10 d) after adoptive cell transfer, in all donor–recip-
ient combinations, CD4 T cells were found in the lamina
propria of the small bowel and also, in slightly lower num-
bers, in the colon. 24 d after adoptive cell transfer, the fre-
quency of colonic CD4 T cells recovered from the recipi-
ents of CD41CD45RBhi T cells varied considerably among
individual animals. However, no clear correlation between
the frequency of CD4 T cells recovered from the inflam-
matory infiltrates of the colon and development of or pro-
tection from colitis was found. A possible explanation for
the presence of CD4 T cells in the intestinal lamina propria
might be the TNF-independent expression of MAdCAM
(mucosal addressin cellular adhesion molecule) 1 on endo-
thelial cells in the small intestine, which we also observed
in TNF2/2RAG22/2 mice before adoptive cell transfer (data
not shown).1489 Corazza et al.
Although clinical signs of colitis are completely abro-
gated in the absence of TNF, histopathological analyses re-
vealed in some recipients moderate alterations of the large
intestinal mucosa. The enhanced cellularity of the colonic
mucosa (colitis score $7) was always associated with en-
hanced expression of IFN-g at a protein and mRNA level.
This is in agreement with previous reports that indicated an
involvement of IFN-g in the induction of inflammatory
reactions in the colonic mucosa (6, 15, 48). The function of
IFN-g in the pathogenesis of colitis, however, seems to be
nonessential, as described by the recent report by Simpson
et al., who clearly demonstrated a redundant role of IFN-g
in the CD41CD45RBhi transfer model and the bone mar-
row transplantation into tge26 transgenic mouse model of
colitis (23). In agreement with this notion is our calculation
of the absolute numbers of IFN-g–producing cells isolated
from the colons of recipients of CD41CD45RBhi T cells
24 d after transfer that revealed no clear correlation between
the number of IFN-g–secreting cells and presence or ab-
sence of severe colitis (data not shown).
In conclusion, we provide evidence that (a) resident non-T
cells are induced in situ directly or indirectly by CD4 T
cells to produce TNF, which is essential for the develop-
ment of clinical signs of colitis; (b) TNF produced by CD4
T cells alone is not sufficient to induce colitis; (c) activation
of resident non-T cells by CD4 T cells is not TNF depen-
dent, and hence, other mechanisms, either cell–cell contact
such as CD40–CD40 ligand interactions (49) or soluble me-
diators are involved in the induction of TNF-a production
in non-T cells of the affected colonic mucosa; and (d) the
functions exerted by TNF-a in the development of colitis
can not be compensated for by LT-a.
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